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S U M M A R Y
The isolation of Aureimonas altamirensis (a rare opportunistic pathogen with a yet unresolved
pathogenicity) from the ascites ﬂuid of a patient with bacterial peritonitis is reported. The strain was ﬁrst
identiﬁed by matrix-assisted laser desorption/ionization time-of-ﬂight mass spectrometry (MALDI-TOF
MS) and the result was conﬁrmed using 16S rDNA sequencing. An antimicrobial susceptibility proﬁle
was determined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
guidelines published in 2013, revealing sensitivity to all antibiotics tested. The patient was treated
effectively with levoﬂoxacin.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
In 2006, Jurado et al. described a new bacterial species that was
isolated from the subterranean environment of the Altamira cave
in Cantabria, Spain.1 The bacterium belonged to the genus
Aurantimonas and was named Aurantimonas altamirensis.1 These
are Gram-negative, non-motile bacteria that grow in a strictly
aerobic environment exhibiting a yellow colour. Biochemical
testing has revealed positivity in catalase and urease, and oxidase
reaction.1 Furthermore, the ideal growing temperature has been
determined to be between 10 and 40 8C with an optimum at 28 8C.1
Following taxonomic studies that included 16S rDNA sequenc-
ing and the comparison of fatty acid proﬁles, the genus
Aurantimonas was reclassiﬁed in 2008 and renamed Aureimonas.2
To date, only a few reports connect Aureimonas altamirensis with
human infections. These bacteria have been isolated from the
sputum of cystic ﬁbrosis patients, but have also been involved in
ophthalmologic diseases (keratitis) and have caused invasive
infections (pleural effusion, bacteraemia).3–5
We report here, for the ﬁrst time, the isolation of A. altamirensis
in the ascites ﬂuid of a 47-year-old woman suffering from a* Corresponding author. Tel.: +49 351 458 16585; fax: +49 351 458 6310.
E-mail address: percy.schroettner@tu-dresden.de (P. Schro¨ttner).
http://dx.doi.org/10.1016/j.ijid.2014.09.006
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).metastatic cancer of the cholangiocellular or pancreatic system,
presenting with peritonitis.
2. Case report
In October 2013, a 47-year-old woman presented to the
emergency department of the University Hospital Dresden with
progressing ascites and vomiting. The patient’s history showed a
moderately differentiated adenocarcinoma (diagnosed in August
2012 in our institution). Histological analysis suggested that the
primary tumour was either in the cholangiocellular system or in
the pancreas. TNM staging revealed a grade IV tumour with
metastasis in the liver and lymph nodes, as well as with peritoneal
carcinomatosis. The initial treatment consisted of ﬁve courses of
FOLFOXIRI (irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, calcium
folinate 200 mg/m2, and 5-ﬂuorouracil 3200 mg/m2). To diminish
the adverse affects we decided on an 80% dose reduction from the
third course. Because of progressive disease we switched to
cisplatin/gemcitabine (25 mg/m2/1000 mg/m2) in February
2013. However, re-staging in September 2013 showed advanced
metastatic disease in the liver and peritoneum. Although the
patient presented with grade I thrombocytopenia, grade III fatigue,
and grade IV polyneuropathy, she requested the therapy to be
continued. The therapy ended in November 2013.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Antibiotic resistance proﬁle using EUCAST breakpointsa
Antibiotic MIC breakpoint, mg/l Evaluation
according to EUCAST
Ampicillin 0.032 S







EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC,
minimum inhibitory concentration; S, susceptible.
a The antibiotic resistance proﬁle was determined according to the clinical
breakpoint table v. 3.1 published by EUCAST in 2013. Etest strips were used and the
‘non-species related’ breakpoints were used for interpretation. All tested antibiotics
were effective against this Aureimonas altamirensis patient isolate.
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for the ascites (October 2013), chemotherapy was ongoing. She
reported abdominal pain and nausea. Laboratory values showed a
signiﬁcantly elevated C-reactive protein (CRP) of 101.0 mg/l and a
slight leukocytosis of 10.81  109/L. She underwent paracentesis,
which removed 3 l of serous ﬂuid. The ascites had an elevated
white blood cell count of 0.74  109/l and an erythrocyte count of
0.003  1012/L. Subsequently, the patient received oral levoﬂox-
acin. After the ascites puncture, the patient’s physical condition
improved and she returned home. Histological analysis of the
ascites reported no evidence of malignancy, but microbiological
analysis revealed bacterial peritonitis with the detection of
A. altamirensis, sensitive to levoﬂoxacin.
In November 2013 the patient was again admitted to the
hospital due to recurrent ascites. Two weeks prior to this
admission, chemotherapy had been discontinued because of the
adverse effects described above and to continue with best
supportive care. At this time, 5 l of ﬂuid were removed. The cell
count was normal and no malignant cells were found. Unfortu-
nately, at this time point no material was sent to the Institute of
Medical Microbiology. Recurrent increases in the ascites in this
patient, who was in a palliative situation, led to the decision for
permanent drainage of the ascites in order to avoid further
hospitalization. The procedure was done in December 2013. Ini-
tially, 2 l ascites were removed every 2–3 days; the frequency and
amount later decreased to 500–600 ml every 3 days. In January
2014, we were notiﬁed that the patient had died after having spent
2 months at home.
3. Microbiological analysis
Ten millilitres of ascites ﬂuid was inoculated into the blood
culture bottles and was sent to the diagnostic laboratory for
microbiological analysis. They were incubated in an automated
blood culture incubation system (BACTEC 9240; Becton Dickinson,
Heidelberg, Germany) until positivity was indicated. The blood
culture medium was then plated onto Columbia blood agar
containing 5% sheep blood, chocolate agar, and bile–chrysoidin–
glycerol agar for determination of bacterial growth. Additionally,
Mueller–Hinton agar was used to obtain a preliminary resistance
proﬁle via agar dilution method. After incubation for 18 h at 37 8C
and 5% CO2, small yellow colonies grew on blood agar. For
identiﬁcation, matrix-assisted laser desorption/ionization time-of-
ﬂight mass spectrometry (MALDI-TOF MS) (Bruker Daltonics,
Bremen, Germany) was performed resulting in A. altamirensis (mass
spectrometry score 1.927). However, since the interpretation of the
result indicated no reliability at the species level, we conducted a 16S
rDNA analysis. The BLAST algorithm (http://blast.ncbi.nlm.nih.gov)
showed 100% homology with the respective 16S rDNA sequence
deposited in the NCBI nucleotide collection (nr/nt). The antimicro-
bial susceptibility testing results were interpreted according to the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) guidelines published in 2013 (EUCAST clinical breakpoint
table v. 3.1) using the non-species related breakpoints (Table 1).
4. Discussion
The use of mass spectrometry for routine diagnostics in the
microbiology laboratory has become a major advantage for both
routine applications and research purposes. The large number of
reference spectra embedded in the MALDI-TOF MS database permits
the highly conﬁdent identiﬁcation of rarely occurring bacteria. In
this present case, the recently described A. altamirensis was found by
applying mass spectrometry. However, since the score value of
1.927 is too low to secure a reliable identiﬁcation to the species level,
we conducted 16S rDNA sequencing; this revealed a 100% homologyto the A. altamirensis 16S rDNA sequences deposited in the NCBI
nucleotide collection. We were therefore able to conﬁrm the result
from MALDI-TOF MS. Moreover, adding the main spectrum of our
isolate to the MALDI-TOF MS database should lead to better
identiﬁcation for ongoing laboratory diagnostics.
The few case reports published on the involvement of A.
altamirensis in human disease suggest its role as a causative agent
of human infections.3–5 A common characteristic of patients
affected by this pathogen may be dysfunction of the immune
system.4,5 In our case, the patient was suffering from advanced
cancer and was undergoing chemotherapy, thus assuming an
impairment of the patient’s immune system. However, the
immune status of the three patients with A. altamirensis infection
mentioned by Luong et al.3 is not known.
For antimicrobial susceptibility testing, we chose antibiotics that
are frequently used to treat Gram-negative bacteria and applied the
guidelines for ‘non-species related breakpoints’ published by
EUCAST in 2013 (http://www.eucast.org/clinical_breakpoints/).
Our strain was susceptible to penicillins, cephalosporins, carbape-
nems, quinolones, and aminoglycosides. Interestingly, the mini-
mum inhibitory concentration (MIC) values determined here were
extremely low. We therefore propose that this bacterium has not
been confronted with these antibiotics before and there was no need
to develop or express antibiotic resistance mechanisms. However, it
will be necessary to investigate a larger number of these strains to
conﬁrm this assumption.
In conclusion, we report, for the ﬁrst time, the isolation of
A. altamirensis from the ascites ﬂuid of a cancer patient with
bacterial peritonitis. The strain was initially identiﬁed using mass
spectrometry, indicating the usefulness of this method for
detecting rare pathogens. Our strain was susceptible to quinolones
and the patient was treated effectively with levoﬂoxacin. Future
research needs to clarify the pathogenicity of A. altamirensis and its
ability to cause infections in humans.
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